Skip to content

Climb Bio, Inc. CLYM Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Amgen logo
AmgenAMGN
$246.43B+9.9%
Vera Therapeutics logo
Vera TherapeuticsVERA
$2.83B+85.0%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$498.7M+1,393%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$787.38M+114%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$638.62M

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Calculated from Climb Bio, Inc.’s reported figures.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s enterprise value?
Climb Bio, Inc. (CLYM) reported enterprise value of $319.33M in Q1 2026.
How has Climb Bio, Inc.'s enterprise value changed year-over-year?
Climb Bio, Inc.'s enterprise value increased by 493.8% year-over-year, from $53.77M to $319.33M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.